State-of-the-art technology in genomic sequencing has dramatically accelerated biomedical research to a point where tailored genomic approaches will soon be readily accessible to patients. Cancer treatment has already begun to incorporate sequence results into clinical decision-making;here, subsets of cancer are defined by individual genetic characteristics that inform treatment choices. Since common cancer subtypes have been the topic of large-scale genome projects, patients who have rare, poorly characterized cancers without standard therapies have much to gain through clinical tumor sequencing in Projects i and 2. However, if the clinical promise of such personalized medicine is to be realized, the psychosocial implications of genome sequence results must be better understood, effective health communication techniques developed, and ethical dilemmas addressed. For example, how will we decide when sequence results are "ready for prime time" (i.e., suitable for use and disclosure in a clinical setting)? Consensus policies that are based on ethical principles and incorporate patient viewpoints will need to be developed for genomic applications in clinical medicine. Also required will be an evidence-based plan for managing incidental findings and optimally presenting clinical or personally meaningful results. We know for example, that genetic education and counseling approaches that fail to incorporate best practices in health and risk communication can overwhelm patients'information-processing capacities. In addition, patient preferences for information may require physicians to consider not only the clinical utility of testing, but also how to address patients'"personal utility" values. This recognition will be especially important as sequencing inevitably generates findings (e.g., germline mutations) that are unrelated to the presenting cancer but nonetheless of interest to patients and/or their biological relatives. Furthermore, we need data on how patients actually respond to sequence results in order to understand how this novel information affects the likelihood and extent of potential psychosocial benefits (e.g., positive behavior changes) and harms (e.g., misunderstanding, distress). By addressing the aforementioned needs, our project will bring much-desired evidence to the vigorous debate about the appropriate use of genomic sequence information in medicine.

Agency
National Institute of Health (NIH)
Institute
National Human Genome Research Institute (NHGRI)
Type
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
1UM1HG006508-01A1
Application #
8665545
Study Section
Special Emphasis Panel (ZHG1-HGR-N (J2))
Project Start
Project End
Budget Start
2013-07-19
Budget End
2014-05-31
Support Year
1
Fiscal Year
2013
Total Cost
$352,117
Indirect Cost
$125,675
Name
University of Michigan Ann Arbor
Department
Type
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Gornick, Michele C; Scherer, Aaron M; Sutton, Erica J et al. (2016) Effect of Public Deliberation on Attitudes toward Return of Secondary Results in Genomic Sequencing. J Genet Couns :
Amendola, Laura M; Jarvik, Gail P; Leo, Michael C et al. (2016) Performance of ACMG-AMP Variant-Interpretation Guidelines among Nine Laboratories in the Clinical Sequencing Exploratory Research Consortium. Am J Hum Genet 98:1067-76
Everett, Jessica N; Mody, Rajen J; Stoffel, Elena M et al. (2016) Incorporating genetic counseling into clinical care for children and adolescents with cancer. Future Oncol 12:883-6
Rasmussen, Luke V; Overby, Casey L; Connolly, John et al. (2016) Practical considerations for implementing genomic information resources. Experiences from eMERGE and CSER. Appl Clin Inform 7:870-82
Roychowdhury, Sameek; Chinnaiyan, Arul M (2016) Translating cancer genomes and transcriptomes for precision oncology. CA Cancer J Clin 66:75-88
O'Daniel, Julianne M; McLaughlin, Heather M; Amendola, Laura M et al. (2016) A survey of current practices for genomic sequencing test interpretation and reporting processes in US laboratories. Genet Med :
Raymond, Victoria M; Gray, Stacy W; Roychowdhury, Sameek et al. (2016) Germline Findings in Tumor-Only Sequencing: Points to Consider for Clinicians and Laboratories. J Natl Cancer Inst 108:
Mehra, Rohit; Vats, Pankaj; Cieslik, Marcin et al. (2016) Biallelic Alteration and Dysregulation of the Hippo Pathway in Mucinous Tubular and Spindle Cell Carcinoma of the Kidney. Cancer Discov 6:1258-1266
Green, Robert C; Goddard, Katrina A B; Jarvik, Gail P et al. (2016) Clinical Sequencing Exploratory Research Consortium: Accelerating Evidence-Based Practice of Genomic Medicine. Am J Hum Genet 98:1051-66
Brothers, Kyle B; Holm, Ingrid A; Childerhose, Janet E et al. (2016) When Participants in Genomic Research Grow Up: Contact and Consent at the Age of Majority. J Pediatr 168:226-31.e1

Showing the most recent 10 out of 28 publications